ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL

Court of Appeals of Georgia·Decided July 27, 2023·No. A23A1096·Published

Opinion

FIRST DIVISION

BARNES, P. J.,

LAND and, WATKINS, JJ.

NOTICE: Motions for reconsideration must be physically received in our clerk’s office within ten days of the date of decision to be deemed timely filed.

https://www.gaappeals.us/rules

July 27, 2023

In the Court of Appeals of Georgia A23A1096. ALPHA GENOMIX LABORATORIES, INC. et al v.

CRANDALL.

BARNES, Presiding Judge.

Shane Crandall sued Alpha Genomix Laboratories, Inc. (“Alpha”) and Consultative Genomics, LLC (“ConGen”), alleging that they owed him severance benefits under his employment contract. Following a bench trial, the trial court entered final judgment in favor of Crandall on his claims for breach of contract and awarded him damages. On appeal, the defendants contend that the judgment should be reversed because Crandall’s employment contract failed for lack of consideration; the employment contract was unenforceable because Alpha’s CEO and Crandall violated their fiduciary duties and acted in bad faith in executing the contract; there was no “change in control” that triggered the payment of severance benefits under the

employment contract; ConGen did not assume liability for breach of the employment contract when it acquired all of Alpha’s shares; Crandall was barred from bringing suit under a contractual indemnification provision; and the severance provision of the employment contract was invalid because it violated the federal Eliminating Kickbacks in Recovery Act (“EKRA”), 18 USC § 220.

For the reasons discussed below, we vacate the judgment in part and remand for the trial court to consider under the proper legal framework whether ConGen assumed liability for breach of the employment contract when it acquired the shares of Alpha. On remand, the trial court also should address two other issues that were raised below but were not ruled on by the court in its judgment: whether Crandall’s claims are barred by the contractual indemnification provision or by EKRA. We affirm the judgment in all other respects.

Construed in favor of the judgment,1 the evidence presented at the bench trial showed that Alpha is a medical testing laboratory located in Peachtree Corners, Georgia, which was acquired by ConGen in December 2018. Before the acquisition, Alpha was owned by 28 shareholders. The shareholders did not take part in the day-

1 See Gibson v. Gibson, 301 Ga. 622, 624 (801 SE2d 40) (2017).

to-day operations of Alpha and did not vote on operational issues like the execution of contracts. One of Alpha’s shareholders, Hani El Shawa, served as its CEO and on its three-member Board of Directors. Alpha’s largest shareholder, Richard Sasnett, served as its Executive Vice President of Sales and as a Board member. Prior to December 2018, Alpha had no bylaws governing its officers and directors.

Crandall’s Employment at Alpha before the ConGen Acquisition. In April 2016, Alpha hired Crandall to serve as an Area Sales Director. While serving in that position, Crandall reported to Sasnett. In the summer of 2017, Crandall engaged in discussions with El Shawa, Sasnett, and another Area Sales Director about developing and marketing new product lines. As a result of those discussions, El Shawa and Sasnett made the decision to promote Crandall to a newly created position of National Sales Director — Oncology & Women’s Health, where he would continue to report to Sasnett but would have expanded job responsibilities. In his new position, Crandall would lead sales representatives in their efforts to identify physicians who had patients who could benefit from Alpha’s testing capabilities. However, Crandall would not have authority to hire or fire employees, set employees’ salaries, or sign employment contracts on behalf of Alpha.

In light of his promotion, the parties agreed that Alpha would provide Crandall with a new employment agreement that included an increase in salary and commissions. Additionally, because there was talk at Alpha that it might be acquired by another entity or become a publicly traded company, the parties agreed that Crandall’s new employment agreement would include a severance provision addressing a change in control in the management of the company.

Crandall began serving in his new National Sales Director position based on assurances from El Shawa and Sasnett that his written employment agreement soon would be finalized, with its terms and conditions applied retroactively. El Shawa provided Crandall with several drafts of the employment agreement over the ensuing months. The draft agreements were prepared by Alpha’s counsel, who also were shareholders of the company. All three of Alpha’s Board members (El Shawa, Sasnett, and the third member) were aware of the negotiations and discussed with legal counsel the terms and conditions to include in Crandall’s employment agreement.

In May 2018, El Shawa emailed Crandall the version of the employment agreement that ultimately was executed by the parties. After several more months passed in which Crandall continued to inquire about when his employment agreement

would be executed, El Shawa called Crandall to his office on December 12, 2018. On that date, El Shawa, in his capacity as Alpha’s CEO, and Crandall signed the employment agreement (“Employment Agreement” or “Agreement”). El Shawa, Sasnett, and other members of Alpha’s executive management team also signed new employment agreements at the same time as Crandall.

Crandall’s Employment Agreement included an increase in salary and commissions in return for Crandall serving in his new National Sales Director position. The Employment Agreement established an initial two-year term for Crandall’s employment in his new position, subject to renewal, and included several provisions addressing termination of Crandall’s employment and severance pay in the event of his termination. Among other severance provisions, the Employment Agreement included a provision pertaining to a change in control in management at Alpha that is at the center of the dispute in this case (“Change-in-Control Provision”). The Change-in-Control Provision stated:

7.5 By Employee upon a Change of Control. (a) In the event of a Change in Control (as defined below), Employee [Crandall] shall have the right to terminate his employment hereunder by giving a written notice of termination to the Company [Alpha] within ninety (90) days after the date a Change in Control occurs. If Company terminates

Employee’s employment (or provides a notice of termination to Employee) within the ninety (90) day period after the date a Change in Control occurs and such termination is not for Cause pursuant to Section 7.4 above, such termination shall have the same effect as if the Employee had submitted his notice of termination to the Company pursuant to this Section 7.5. The parties agree that, if Employee terminates his employment pursuant to this Section 7.5 (or is deemed to have terminated his employment pursuant to this Section 7.5 as provided in the previous sentence), Employee shall be entitled to the following benefits:

(i) Base Salary. Employee shall receive his then current Base Salary for a period of twelve (12) months following the Termination Date payable in the same manner as it was being paid as of the Termination Date (subject to withholding of all applicable taxes). Alternatively, Company in its sold discretion, may pay the amounts owed to Employee in this Section 7.5 (a) (i) in one lump sum payment, subject to withholding of all applicable taxes.

(ii) Commission. The Company shall pay Employee an amount equal to the Commission paid to Employee pursuant to Section 4.2 during his last full employment year. Said amount shall be payable in one lump sum payment, subject to withholding of all applicable taxes.

(iii) Health Coverage, Life Insurance, and Disability Insurance.

Free access — add to your briefcase to read the full text and ask questions with AI

ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL, (Ga. Ct. App. 2023).

ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL (ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bullington v. Union Tool Corp.
328 S.E.2d 726 (Supreme Court of Georgia, 1985)
Bowen Builders Group, Inc. v. Reed
555 S.E.2d 745 (Court of Appeals of Georgia, 2001)
ROYAL CROWN COMPANIES v. McMahon
359 S.E.2d 379 (Court of Appeals of Georgia, 1987)
Brown Transport Corp. v. Street
391 S.E.2d 699 (Court of Appeals of Georgia, 1990)
Coleman v. Daimlerchrysler Services of North America, LLC
623 S.E.2d 189 (Court of Appeals of Georgia, 2005)
Speed v. Muhanna
619 S.E.2d 324 (Court of Appeals of Georgia, 2005)
Williamson v. STRICKLAND & SMITH, INC.
673 S.E.2d 858 (Court of Appeals of Georgia, 2009)
Mon Ami International, Inc. v. Gale
592 S.E.2d 83 (Court of Appeals of Georgia, 2003)
Jerry Dickerson Presents, Inc. v. Concert/Southern Chastain Promotions
579 S.E.2d 761 (Court of Appeals of Georgia, 2003)
BDI Laguna Holdings, Inc. v. Marsh
689 S.E.2d 39 (Court of Appeals of Georgia, 2009)
Edwards v. Grapefields, Inc.
599 S.E.2d 489 (Court of Appeals of Georgia, 2004)
Shelby Insurance v. Ford
454 S.E.2d 464 (Supreme Court of Georgia, 1995)
Tattersall Club Corp. v. White
501 S.E.2d 851 (Court of Appeals of Georgia, 1998)
Glisson v. Global Security Services, LLC
653 S.E.2d 85 (Court of Appeals of Georgia, 2007)
BAARS v. Freeman
708 S.E.2d 273 (Supreme Court of Georgia, 2011)
Woods v. Hall
726 S.E.2d 596 (Court of Appeals of Georgia, 2012)
Federal Deposit Insurance Corp. v. Loudermilk
761 S.E.2d 332 (Supreme Court of Georgia, 2014)
Mosaic Business Advisory Services, Inc. v. Stone
784 S.E.2d 426 (Court of Appeals of Georgia, 2016)
City of Atlanta v. Mays
801 S.E.2d 1 (Supreme Court of Georgia, 2017)
Gibson v. Gibson
801 S.E.2d 40 (Supreme Court of Georgia, 2017)